126 related articles for article (PubMed ID: 30146822)
1. Clinical Application of Pro-Gastrin-Releasing Peptide.
Fang L; Huang Z; Lin Y; Fu J; Liang X; Liu F
Clin Lab; 2018 Jul; 64(7):1259-1268. PubMed ID: 30146822
[TBL] [Abstract][Full Text] [Related]
2. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
5. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
7. Reference intervals for plasma pro-gastrin releasing peptide (ProGRP) levels in healthy adults of Chinese Han ethnicity.
Zhang J; Zhao Y; Chen Y
Int J Biol Markers; 2014 Dec; 29(4):e436-9. PubMed ID: 24723213
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
[TBL] [Abstract][Full Text] [Related]
9. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
10. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
11. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
12. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
13. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
[TBL] [Abstract][Full Text] [Related]
14. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
Yang HJ; Gu Y; Chen C; Xu C; Bao YX
Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
[TBL] [Abstract][Full Text] [Related]
16. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels.
Goto K; Kodama T; Hojo F; Kubota K; Kakinuma R; Matsumoto T; Ohmatsu H; Sekine I; Nagai K; Nishiwaki Y
Cancer; 1998 Mar; 82(6):1056-61. PubMed ID: 9506349
[TBL] [Abstract][Full Text] [Related]
18. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
[TBL] [Abstract][Full Text] [Related]
19. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
20. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].
Chen YJ; Jin WD; Yang GY; Zhou YL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
